



Abstract— The literature has long argued that the effectiveness 
of HIV/AIDS interventions depends on the contexts of their 
implementation. However, estimates of the relative costs, 
effectiveness and cost-effectiveness of HIV/AIDS interventions in 
socio-economic contexts such as rural and urban areas in South 
Africa are insufficient to guide policy makers in resource 
allocations. This paper uses Markov states transition models to 
provide and compare such estimates for prevention of mother-to-
child transmission (PMTCT), highly active antiretroviral therapy 
(HAART) for adults, and HAART for children. Data for the 
baseline costs and health outcomes are collected in the literature. 
To capture the effect of a given HIV/AIDS intervention and the 
area of its implementation, transitions in HIV/AIDS states over 
time are pegged to projections of Spectrum Policy Modeling 
System in that area.  The results suggest that the extent to which 
cost-effectiveness of HIV/AIDS interventions across a rural area 
and an urban area are different is great. Policy makers should 
allocate resources according to these CE variations.  
 




HE  amount of resources committed to HIV/AIDS by the 
South African government, as part of its effort to reduce 
the impact of the epidemic, has been increasing since 2007. 
Further efforts in resource management are however required 
in order to maximise health outcomes from available 
resources. One of such efforts is to intensify resources in rural 
and urban areas according to the relative cost-effectiveness of 
HIV/AIDS interventions in such areas. This approach to 
policy making is however facilitated by relative cost-
effectiveness estimates, which have not been produced for 
major HIV/AIDS interventions. This paper aims to provide 
such estimates.. 
The impact of HIV/AIDS in South Africa, though 
stabilizing, remains high. The prevalence of HIV/AIDS in the 
general population grew from almost 0 in 1985 to 11.2% in 
2007 and stabilized around this level since [1]. With 
prevalence being the sum of new infections and surviving 
HIV population, stabilization of prevalence in the era of 
HAART-induced survival implies a reduction in the infection  
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rate. The number of annual new infections was estimated at 
511,000 in 2000, 101,000 in 2013 and is projected decrease to 
61,235 in 2020 [2]. The number of annual AIDS deaths were 
estimated to be 118,000 in 2000, 196, 000 in 2013 and is 
projected to be 135,000 in 2020 [2]. Significant reduction of 
the impacts of HIV/AIDS requires more commitment to the 
response. The usual scarcity of resources coupled with an 
unfavorable economic outlook both nationally and 
internationally implies that such commitments focus on 
approaches to manage available resources efficiently. 
Intensifying resources in rural and urban areas in South Africa 
according to how HIV/AIDS interventions are relatively cost-
effective in these areas is one of such approaches as informed 
by theoretical explanations and some empirical evidence. .  
Theoretical expositions insinuate that the cost-effectiveness 
in socio-economic areas, such as a rural area and an urban 
area, are due to be different.  The theory of the socio-
economic determinants of health proposes that the impact of 
HIV/AIDS is lower in an area with higher socio-economic 
status [3], an urban area for example. The theory predicts that 
factors prevailing in a higher socioeconomic status such as 
high levels of income, education, are conducive to favorable 
health conditions and avoidance of risky behaviour. This 
prediction implies that the impact of HIV/AIDS is higher in a 
rural area than it is in an urban area. It further implies that the 
effectiveness of an HIV/AIDS intervention is lower in a rural 
area than it is in an urban area, on the understanding that the 
effectiveness of an HIV/AIDS intervention is measured as the 
extent to which it reduces the impact of HIV/AIDS. Lower 
reduction in the impact of HIV/AIDS in a rural area by a 
standard HIV intervention for a rural area and an urban area is 
explained by more impact of HIV/AIDS in a rural area and by 
the unlikelihood of the standard intervention to address 
specifically factors causing difference in the impact of 
HIV/AIDS across areas. .  
The difference in the impact of HIV/AIDS across a rural 
area and an urban area as a result of interaction between the 
intervention and the area implies also the difference in costs 
across areas. The difference in the cost of an HIV/AIDS 
intervention in a rural area and an urban area can be grasped 
through the realization that an HIV/AIDS intervention 
earmarks specific activities to the impact. For example, 
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specific procedures are earmarked to patients whose CD4 
count has reached a critical stage while a set of procedures are 
planned for patients with mild conditions. Since these impacts 
of HIV/AIDS are caused or originate from contextual factors 
and since this health impacts influence the activities of an 
HIV/AIDS intervention, contextual factors influence the costs 
of HIV/AIDS interventions. The difference in the extent of 
these factors across areas implies that areas may influence 
differently the costs of an HIV/AIDS intervention. 
The above prediction of the theory of socio-economic 
determinants of health is founded on the assumption that 
contextual factors influence on average individual behaviours 
and attitudes towards HIV/AIDS intervention in a similar 
manner. This may however not be always the case. Other 
theories formulate individual-specific factors which act 
independently of the contextual factors. Psychosocial theories 
for example explain that risk behaviours or attitudes towards 
HIV interventions depend on the individual ability and 
willingness to learn about change in such behaviours or 
attitudes ([4], [5], [6]). Economic theory explains that unsafe 
risk behaviour, i.e. risky sexual behaviour or risky attitude 
towards health interventions, is based on the cost and utility 
analysis between sexual partners, or the cost and utility 
analysis of patients with respect to using a specific HIV/AIDS 
intervention ([7],[8],[9],[10],[11]). Epidemiological theories 
focus less on individual behaviours but on epidemic 
behaviour, thus highlighting the fact that the risk of infections 
and the effectiveness of interventions depend largely on HIV 
prevalence within particular area [12]. These theoretical 
exposés imply complex outcomes from interaction of each 
area factors and an HIV/AIDS intervention, which in turn 
entail potential variation in cost-effectiveness of HIV/AIDS 
interventions across areas. Variation in cost-effectiveness of 
an HIV/AIDS intervention across rural area and an urban area 
brings about opportunities to increase efficiency in resource 
allocations.  
Empirically, studies showed that the effectiveness of 
HIV/AIDS interventions depend on the area or context of 
implementation ([13], [14]). The evidence revealed that most 
of the factors underlying the impact of HIV/AIDS in a given 
context prevail in patterns that are different from the patterns 
in another context and that these factors indirectly influence 
the impact (effectiveness) of HIV/AIDS interventions [15]. 
For instance, one study comparing the effectiveness of 
treating STDs to prevent HIV transmission in a low 
prevalence area (Tanzania) and a relatively high prevalence 
one (Uganda) found that the treatment of STDs reduced HIV 
transmission to a greater degree in Tanzania than in Uganda 
[16]. The factors underlying the difference in effectiveness 
was that in the latter country, HIV transmission was taking 
place outside the core groups with high STI rates, which were 
being targeted by STI interventions [16]. Even in comparable 
socio-economic areas, evidence showed that the impact of 
HIV/AIDS and implied effectiveness of HIV/AIDS 
interventions were different.  Reference [17] found that risk 
factors such as early sexual debut were important 
determinants of infections in urban populations with high 
prevalence (Ndola and Kisumu) while these factors were less 
important in urban populations with low HIV prevalence 
(Cotonou and Yaoundé), making prevalence a factor likely to 
explain difference in effectiveness of HIV/AIDS interventions 
across these similar socio-economic areas. Cost-effectiveness 
evidence has also varied across areas with not consistent 
explanation of the differences ([18], [19], [20]).   
Theoretical uncertainty and empirical insights above 
insinuate potential variation in cost-effectiveness of 
HIV/AIDS interventions across a rural area and an urban area 
in South Africa, which would be crucial to policy making. In 
fact, if cost-effectiveness of HIV/AIDS interventions varies to 
great extent across rural and urban areas, it would provide 
policy makers with an opportunity to increase efficiency in 
resource allocations by intensifying resources according to 
how cost-effectiveness of HIV/AIDS interventions compares 
in these areas. This relative cost-effectiveness evidence has 
however remained insufficient and this paper contributes to its 
estimation.  .  
I. METHODS 
Such estimation requires a follow up of patients in 
HIV/AIDS interventions in each area over time and a record 
of costs and health outcomes. As this is costly and can only 
provide estimates up to the point of follow up while policy 
makers need estimates that incorporate long term for planning 
purpose, modeling is an alternative. This paper uses Markov 
states transition models.  
A Markov states transition model tracks a hypothetical 
cohort of patients in successive periods (cycles) of equal 
intervals over a specific time horizon of an HIV/AIDS 
intervention. In each cycle, the hypothetical population is 
distributed in mutually exclusive HIV/AIDS states, i.e.  a 
patient cannot be in two HIV/AIDS states in one period. In 
each period, costs and health outcomes relevant to a given 
HIV state are applied to the number of patients in that state. 
The costs and health outcomes of successive periods are then 
summed up. In case many Markov models are used, the results 
of the models are compared. Markov modeling is appropriate 
for chronic diseases in which patients move fort and back in 
different health states ([21], [22]) such as HIV/AIDS. Markov 
modeling has been extensively used in the literature to model 
HIV/AIDS interventions ([23], [24], [25], [26], [27], and 
[28]).  
In this paper, hypothetical cohorts of patients are tracked 
over time in various HIV/AIDS states using Markov states 
transition models. Specifically, two pairs of Markov states 
transition models are constructed for each intervention. One 
pair of models is analysed in a rural area and another pair in 
an urban area. In each area, one Markov states transition 
model tracks a hypothetical cohort of 100,000 patients in 
successive three-month periods over the lifetime of the cohort 
(until 95% of patients die) in an HIV/AIDS intervention. 
Another model tracks a hypothetical cohort of 100,000 
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patients in successive three-month periods over their lifetime 
in USUAL CARE. The cohort is assumed to be similar to the 
population of patients who would have been using HIV/AIDS 
interventions since 2007. The year 2007 is chosen as the 
starting point of simulation because it is the year which 
marked the South African Government’s serious commitment 
to tackle the HIV epidemic [29]. This study aims to advise 
South African policy makers on the economic implications of 
such a commitment. The interventions modeled are PMTCT, 
HAART FOR ADULTS and HAART FOR CHILDREN.  
For PMTCT, patients are tracked in “uninfected’, 
“infected”, “AIDS” and “dead” HIV/AIDS states and those 
who develop AIDS are directly linked to care.  It is assumed 
that a cohort of 100,000 pregnancies in infected mothers starts 
in the “uninfected” state; within 3 months, some progress to 
the “infected” state, others to the “AIDS” state and others to 
the “dead” state. The cohort of HIV-positive pregnant women 
is assumed to be on dual therapy PMTCT consisting of 
Zidovudine (AZT) at 28th week of pregnancy and during 
labour, followed by Nevirapine (NV) for the new-born baby. 
The cohort is assumed to reflect HIV-positive pregnant 
women in South Africa for 2007 in each area. Of these 
women, 20% exclusively breastfeed, 62% exclusively use 
formula milk and 18% use mixed feeding [30]. It is assumed 
that in the absence of PMTCT, patients use USUAL CARE 
(antenatal care) in which case the Markov states transition 
model tracks these patients in similar HIV/AIDS states 
modeled for PMTCT. 
For HAART FOR ADULTS, a cohort of 100,000 HIV 
infected adults starts in the “AIDS” state, that is, when their 
CD4 count is below 200 . Then, in each of the successive 3-
month periods, some members of the cohort remain in the 
HIV/AIDS state; others improve in health status to CD4 count 
above 200, that is, to “non-AIDS” while the rest worsen to 
“dead” HIIV/AIDS state. The cohort is assumed to have the 
socio-economic characteristics of HIV infected adults in 2007. 
In the absence of HAART FOR ADULTS, patients use usual 
health care services in which case the Markov model tracks 
 these patients in similar HIV/AIDS states modeled for 
HAART FOR ADULTS. 
For HAART FOR CHILDREN, a cohort of 100,000 HIV 
infected children starts in the “AIDS” state. Then, in each of 
the successive 3-month periods, some members of the cohort 
remain in the “AIDS” state; others improve in health status to 
“non-AIDS” state while the rest worsen to “dead” state.  
AIDS in children is defined as a stage at which there is severe 
illness, that is, stages 3 and 4 of the WHO (WHO, 2005).  It is 
assumed that the cohort uses pediatric care (USUAL CARE) 
in the absence of HAART FOR CHILDREN in which case the 
Markov model tracks these patients in similar HIV/AIDS 
states modeled for HAART FOR CHILDREN. The cohort is 
assumed to have the socio-economic characteristics of HIV 
infected children in 2007.  
The base-line costs and health outcomes, i.e. the costs and 
health outcomes in the first three-month Markov period are 
estimated on the basis of cost, health outcomes evidence 
collected in the literature. The hypothetical cohort is applied 
to the proportion of patients (transition probabilities) in each 
HIV/AIDS state to determine the number of patients in that 
HIV/AIDS sate. Then cost data and health outcomes relevant 
to each HIV/AIDS state from the literature are applied to 
patients in that HIV/AIDS state to determine the cost, health 
outcomes of the first  three-month Markov period.  Table 1-
Table 3 provides a summary of transition probabilities, costs 
and health outcomes (quality of life) for each model. Though 
costs, transition probabilities and health outcomes are 
collected from many sources, Table 1-Table 3 show only few 
sources. The source(s) cited is (are) selected on the basis that 
it (they) contains the best evidence or has (have) a value close 
to an average of values from different sources.  
 
 
Table: 1 Transition probabilities data for the base-case comparison (PMTCT, HAART FOR ADULS and their related 
USUALCARE) 
PMTCT Rural context Urban context 


















Non-infected to death 
Infected to AIDS 
Infected to death 

































USUAL CARE Rural context Urban context 
Transition probability BCV Range Source BCV Range Source 
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Non-infected to death 
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Infected to death 

































Rural context Urban context 
Transition probability BCV Range Source BCV Range Source 
Non-AIDS to AIDS 
Non –AIDS to death 





























USUAL CARE Rural context Urban context 
Transition probability BCV Range Source BCV Range Source 
Non-AIDS to AIDS 
Non –AIDS to death 
AIDS to non-AIDS 





























Rural context Urban context 
 
Non-AIDS to AIDS 
Non –AIDS to death 
AIDS to non-AIDS 
Aids death 

























USUAL CARE Rural context Urban context 
 
 
Non-AIDS to AIDS 
Non –AIDS to death 
AIDS to non-AIDS 
AIDS to death 
 



























1 The literature documents that in the absence of HAART, no patients who start in the AIDS state would move to Non-aids State. Such patients would instead 
see their health deteriorates [27] (Badri et al., 2006: 65). Since no patients move from AIDS to non-AIDS in USUAL CARE, so no patients would transit from 
non-AIDS to any other HIV state.  
 
Table 2 Three-month cost data for the base-case comparison (government perspective) 
                                                                      PMTCT intervention  
                              Rural context                          Urban context   
HIV/AIDS 
states  
Base-case value  Source  Value  Sources  





















                                                                     USUAL CARE 
HIV/AIDS state  Value  Source  Value  Sources  
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Note: The cost in “death” was considered as once-off cost in the estimation of the cost for the cohort.  
 
Table 3 Quality of life data used in an intervention2. 
 
2 The quality of life data were obtained from quality of life studies in South Africa ([46],[47],[48]). The quality of life in a. rural context was approximated 
with the average quality of life of people who live predominantly a rural context, the black population. Similarly, the quality of life for the urban context was 





































To get the costs, health outcomes in subsequent three-
month Markov periods, the baseline cost and quality of life 
are applied to changing transition probabilities. Changes in 
transition probabilities in HIV/AIDS state over time in 
successive three-month Markov period is pegged on the trends 
suggested by the projections by Spectrum Policy Modeling 
systems [32] which is a separate model used to models 
interactions between area and each  HIV/AIDS intervention. 
The total costs health outcomes are discounted at 3% 






































recommendations [49]. Given that South African government 
is the main funder of HIV/AIDS interventions, the costs are 
evaluated from government perspective although results of the 
societal perspective are also shown for the sake of comparison 
with studies elsewhere. Average estimates of waiting time, 
transport costs and funeral costs are added to the cost of the 
government perspective to determine the costs of the societal 
perspective. Real costs are also considered using 2007 as the 
base-year. Probabilistic sensitivity analysis is finally 
conducted to take into account the uncertainty underlying the 
analyses. All these analyses are conducted using TreeAge Pro 
HIV state                 Rural  
context  
                         Urban  context   
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and are presented next.   
II. RESULTS  
A. Relative costs 
The relative costs of HIV/AIDS interventions in rural and  
                       
urban areas of South Africa are presented first. Figure 1 
depicts the graphical analysis of such costs (Note that in the 
figure the word context is used while the text talks about area. 
































Source: Author, based on the results of Markov models’ simulations. 
Figure: 1 Overall comparison of the lifetime cost of HIV/AIDS interventions across a rural area and an urban area (in US$, government 
perspective)    
 
The figure depicts that the cost of HIV/AIDS interventions 
over time are lower in a rural area than they are in an urban 
area of South Africa. The Figure shows for example that at 
period 10 of Markov model, PMTCT costs about a third of 
US$5,000,000 in a rural area while at the same period it costs 
about US $10,000,000. At period 10, the cost of USUAL 
CARE related to PMTCT is about a third of US$ 5,000,000 in 
a rural area while it is about half of US$5, 000,000 in the  
 
urban area. The results for other intervention present similar 
patterns although the differences between the costs of USUAL 
CARE related to HAART interventions in a rural area and the 
costs of USUAL CARE related to HAART interventions an 
urban area are not different. Given that the model assumes a 
same size of hypothetical patients in each area, it can be 
concluded that the costs of HIV/AIDS interventions are 
relatively lower in a rural area than they are in an urban area.  
PMTCT 
Panel 1                                               Panel 2 
     
HAART FOR ADULTS 
Panel 3                                           Panel 4 
      
HAART FOR CHILDREN 
Panel 5                                        Panel 6 
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Analyzing relative costs in terms of the difference in costs 
between an HIV/AIDS interventions and its related usual care, 
Figure 1 shows that the gap between USUAL CARE and an 
HIV/AIDS intervention is lower in rural area than it is an 
urban area (Panel 1 to 6). This result suggests that in relation 
to USUAL CARE, an HIV/AIDS intervention in a rural area, 
add less costs to already existing costs of USUAL CARE. In 
other words, relative to USUAL CARE, an HIV/AIDS 
intervention in an urban area results in more incremental costs 
relatively to the incremental costs in a rural area.  The next 











































B. Relative effectiveness  
 
Defining the effectiveness as additional health outcomes of 
an intervention relative to health outcomes of a given 
situation, the effectiveness of an HIV/AIDS intervention in a 
rural area is analysed relative to health outcomes in an urban 
area while the effectiveness of an HIV/AIDS intervention in a 
given area, is analysed relative to health outcomes of USUAL 
CARE. The effectiveness analysis starts with survival as 
health outcomes and then move on to survival adjusted with 
quality of life. The results of survival in rural and urban areas 
are presented in Figure 2. 






































Source: Author, based on the results of Markov models’ simulations. 
Figure 2: Comparison of HIV/AIDS interventions-induced survival in rural urban areas.  
  
PMTCT 
Panel 1                                             Panel 2 
  
HAART FOR ADULTS 
Panel 3                                               Panel 4 
   
HAART FOR CHILDREN 
Panel 5                                            Panel 6 
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Figure 2 shows that the patterns of survival over time in 
rural and urban areas in South Africa are different for both 
HIV/AIDS interventions and related USUAL CARE. 
Specifically, survival is generally lower in a rural area than it 
is in an urban area.  The figure shows for example that at 
Markov period 10, 26% of the cohort using PMTCT survives 
in rural area while the corresponding figure for the urban area 
is 40%. At the same period, survival with USUAL CARE in a 
rural area is 18% while survival in an urban area is about 
26%. It is to note however that while survival under HAART 
is clearly lower in a rural area than it is  in an urban area, the 
patterns of survival under HAART-related USUAL CARE  is 
not clearly different in a rural  area and an urban area. At 
Markov period 50 for example, survival under HAART FOR 
ADULTS-related USUAL CARE is about 40% in a rural area 
while it is about 0% an urban area although earlier at Markov 
period 10, survival under HAART–related USUAL CARE is 
consistent with patterns of survival for HIV/AIDS 
interventions. These results indicate that under USUAL 
CARE, a proportion of patients resisting the epidemic in the 
rural area might be greater than the proportion of patients 
resisting the epidemic in an urban area.  
Comparing survival in each area, Figure 2 shows that, as 
expected, survival in USUAL CARE is less than survival 
under related HIV/AIDS interventions regardless of the area. 
For instance in a rural area, Figure 2, Panel 3 shows that at 
period 10, survival under USUAL CARE is about 15% while 
it is about 50% under related HAART intervention. Similarly 
in an urban area, Panel 6 of the figure show for instance that 
at period 50, survival under USUAL CARE is about 0% while 


























The paper is more interested in the comparison of 
additional survival (incremental effectiveness) of an 
HIV/AIDS intervention across a rural area and an urban area. 
The incremental effectiveness is graphically shown by the gap 
between the USUAL CARE survival curve and a given 
HIV/AIDS survival curve. The results in Figure 2 suggest that 
PMTCT is relatively more effective in a rural area on the basis 
of the gap between the PMTCT survival curve and USUAL 
CARE survival curve, although the difference in the gap 
across area is not that much (Panel 1 and panel 2).  While the 
gap difference between PMTCT and USUAL CARE curves 
across a rural and an urban area is almost insignificant, the 
gap is significant with HAART FOR ADULTS and HAART 
FOR CHILDREN (Panel 3 and Panel 4, Panel 5 and Panel 6).  
The results show that HAART FOR ADULTS and HAART 
FOR CHILDREN are relatively less effective in a rural area 
than they are in an urban area on the basis of the gap between 
survival curves for the two interventions and USUAL CARE 
Figure 2 has compared relative effectiveness of HIV/AIDS 
interventions across a rural area and an urban area using 
survival as a measure of health outcome. Survival may not be 
an accurate measure of health status because  long survival 
can prevail in poor health conditions than short survival such 
that overall, taking into account quality of life, short survival 
might results in greater health outcomes. Discounting also 
makes QALYs gained during later periods of modeling worth 
less than QALYs gained in earlier periods Therefore, this 
paper produced survival (life-years) by multiplying the size of 
hypothetical cohort with proportions of patients surviving in 
each HIV/AIDS state of a Markov period. The result was then 
multiplied with the quality of life  to produce quality-adjusted 
life-years (QALYs) at each period.  The results are illustrated 
in Figure 3. 
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Source: Author, based on the results of Markov models’ simulations.  
Figure 3 Comparison of HIV/AIDS interventions-induced QALYs across rural and urban areas.   
 
 
As Figure 3  shows, except for PMTCT (Panel 1 and Panel 
2), the results in terms of QALYs appear to be consistent with 
the results for survival (Panel 3 and Panel 4, Panel 5 and Panel 
6). The results show that, in relation to USUAL CARE, 
HIV/AIDS interventions are generally more effective in the 
urban area than in the rural area when survival (life-years) are 
adjusted for the quality of life (QALYs) are used as measures 
of effectiveness.  
C. Relative cost-effectiveness  
 
A good grasp of the relative performance of an HIV/AIDS 
intervention in rural and urban areas requires ultimately the 
joint analysis of cost and effectiveness. The numerical results 
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Panel 3                                            Panel 4 
  
Panel 5                                            Panel 6 
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Table 4 Lifetime cost (US$), effectiveness (QALYs) and Cost-effectiveness (US$/QALY) for a cohort of 100,000 patients  
 
Intervention  Rural area Urban area Value in a rural area as a 
% of the value in the 
urban area 
USUAL CARE 
Total costs (GP) 
Total costs (SP) 
Total effectiveness (QALYs) 
PMTCT 
Total cost (GP) 
Total cost (SP) 
Total effectiveness 
Incremental cost  








































Total costs (GP) 
Total cost (SP) 
Total effectiveness  
HAART FOR ADULTS  
Total cost 
Total effectiveness 
Incremental cost  
Incremental effectiveness (QALYs) 
ICER (GP) 



































Total costs  
Total effectiveness  
HAART FOR ADULTS 
Total cost GP 
Total cost SP 
Total effectiveness 
Incremental cost  





































Source: Author, based on the results of Markov models’ simulations.  
 
The results in the Table as to how the costs of an HIV/AIDS 
intervention compare across areas or howeffectiveness of an 
HIV/AIDS intervention compare to those of USUAL CARE is 
consistent with graphical analysis. In the analysis that follows, 
the paper focus on the comparison, across areas, of 
incremental costs, effectiveness, and cost-effectiveness of an 
intervention relative to USUAL CARE   
As for the incremental costs, Table 4 shows the incremental 
cost (IC) of PMTCT in the rural area is less than the IC of 
PMTCT in the urban area. The IC of PMTCT in a rural area 
represents 29% of its IC in the urban area. However, the 
opposite is true for HAART FOR ADULTS and HAART 
FOR CHILDREN whose incremental costs in a rural area 
represent 107% and 179% of their respective incremental cost 
in an urban area. These results indicate that the patterns of 
incremental costs of HIV/AIDS interventions relative to 
USUAL CARE across a rural area and an urban area are not 
the same.  
While the pattern of incremental costs across a rural area 
and an urban area is different across HIV/AIDS interventions, 
the opposite is true for the incremental effectiveness. Table 4 
shows that, the incremental effectiveness of an HIV/AIDS 
intervention is generally lower in a rural area than it is in an 
urban area. For example, the incremental effectiveness of 
PMTCT in a rural area is 53% of its incremental effectiveness 
in an urban area. The corresponding figures for HAART for 
adults and HAART for children are 107% and 179%. These 
results show that HIV/AIDS interventions are less effective in 
a rural area than in an urban one.   
Table 4 further shows that the ICER of PMTCT in a rural 
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area is lower than its ICER in an urban area. Since ICER 
means cost per effectiveness, a lower ICER for PMTCT in a 
rural area means that PMTCT is more cost-effective in the 
rural area than it is in an urban area.  While the results show 
that PMTCT is more cost-effective in a rural area than it is in 
an urban area, they show that HAART FOR ADULTS and 
HAART FOR CHILDREN have greater ICERs in a rural area, 
indicating that they are less cost-effective in this area than 
they are in an urban area. These results indicate that there is 
no specific pattern of CE across areas common to all modeled 
HIV/AIDS interventions.  
The fact that HAART is less cost-effective in a rural area 
can be explained by a number of reasons. First, HAART may 
be adding more to the costs of USUAL CARE than it adds to 
the effectiveness of USUAL CARE in the rural area, resulting 
in greater ICER in the rural area. Alternatively, HAART may 
be adding less to the costs of USUAL CARE than it adds to 
the effectiveness of USUAL CARE in an urban area.   
Defining the equality of the CE of an HIV/AIDS 
intervention across areas as the equality of the ICERs of that 
intervention across these areas, this implies that in case of 
such equality the ICER value in Column 3 of Table 4 would 
be 100. The results in Table 4 show that the ICER value in 
column 3 varies to a greater extent around 100. Measuring the 
extent of CE of an intervention across a rural area and an 
urban area as the distance the ICER value is far away from 
100, the extent of CE of modeled interventions becomes clear 
from Table 5.   
 




Intervention ICER  in a rural area ICER in an urban area ICER in a rural area as % 
of the ICER in an urban 
area 
PMTCT 













Source: Author, based on the results of Markov models’ simulations. 
 
Table 5 shows indeed that the extent of CE of HIV/AIDS 
interventions is different. The table shows that HAART 
interventions are less cost-effective in the rural area than they 
are in the urban area. Their ICER relative to USUAL CARE 
in the rural area is greater than their ICER relative to USUAL 
CARE in the urban area. These ICERs in the rural area 
represent 151% of the ICERs in the urban area.  In contrast, 
PMTCT is more cost-effective in a rural area. Its ICER 
relative to USUAL CARE in a rural area is less than its ICER 
in an urban area to the extent that the ICER in the rural area 
represents 54% of the ICER in the urban area.  
In summary, the results presented in Table 5 suggest that 
there is no specific trend in CE from a rural area to an urban 
area for modeled HIV/AIDS interventions. Furthermore, the 
results show different extent of CE across HIV/AIDS 
interventions. These results were subjected to probabilistic 
sensitivity analysis. Table 6 presents the results of such 
analysis. 
 
Table 6: Results of probabilistic sensitivity analysis assuming no 2010 guidelines (US$, 3% discount rate, Government’s 
perspective) 
  
             Average rural area         Average urban area  
 Intervention  Cost  ($)  (QALYs) Costs ($) QALYs 
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Source: Author, based on the results of Markov models’ simulations. 
 
The results of the probabilistic sensitivity analysis in Table 6 
show that the conclusions of the base-case analysis do not 
change. They are, however, based on the evidence for the 
guidelines before 2010. Further sensitivity analysis is 
conducted to check the comparability of the interventions 
across areas with the implementation of the 2010 guidelines. 
Following the guidelines for PMTCT and HAART issued in 
2010 South Africa adopted earlier HAART treatment in 2011. 
Incorporating the available evidence on earlier treatment and 
earlier PMTCT in base-case values and conducting 
probabilistic sensitivity analysis, the results are reported in 




Table 7 Results of probabilistic sensitivity analysis with 2010 guidelines (3% discount rate, GP) 
 
 Average rural area Average urban area 
Intervention Cost  ($) (QALYs) Costs ($) QALYs 




































































Source: Author, based on the results of Markov models’ simulations
With earlier implementation of PMTCT and HAART, the cost 
per QALY gained decreases. However this does not affect the 
comparability of each intervention across areas.   
III. DISCUSSION OF THE RESULTS   
 
The results in this paper have shown that the ICER of all 
modeled HIV/AIDS interventions across a rural area and an 
urban area are different. This is illustrated by the fact that the 
ICER of an HIV/AIDS intervention in a rural area as a 
percentage of the ICER in an urban area is not 100%.  This 
result suggests that HIV/AIDS interventions are not equally 
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cost-effective across a rural area and an urban area.   
The results have also shown that the trends in CE across a 
rural area and an urban area are not the same. The ICER of 
PMTCT was lower in the rural area than it was in the urban 
area while the ICERs of HAART FOR ADULTS and HAART 
FOR CHILDREN were greater in the rural area than they 
were in an urban area.  This result indicates an absence of 
consistent trends in the CE of HIV/AIDS interventions across 
a rural area and an urban area. A trend would exist if the 
ICER of each HIV/AIDS intervention in a rural area as a 
percentage of the ICER in the urban area is consistently lower 
or greater than 100%. 
Further to the lack of consistent trends in CE of HIV/AIDS 
interventions across a rural area and an urban area, it was 
observed that the extent to which the ICER of an HIV/AIDS 
intervention in a rural area as % of its ICER deviated from 
100% was different across interventions. The ICER of 
PMTCT in a rural area as a percentage of its ICER in an urban 
area was 54% while the corresponding percentages for 
HAART FOR ADULTS and HAART FOR CHILDREN were 
151%.  The fact that the ICERs in a rural area as a percentage 
of the ICERs in an  urban  area is farther away from 100% for 
HAART FOR ADULTS  and HAART FOR CHILDREN than 
it is for PMTCT, indicates that the extent of CE across 
modeled HIV/AIDS interventions is not the same. With the 
ICER meaning the additional costs per health outcome, a 
lower ICER in a given area implies more cost-effectiveness. 
The evidence shows that PMTCT is more cost-effective in the 
rural area than it is in an urban area. By contrast, HAART 
FOR ADULTS and HAART FOR CHILDREN are less cost-
effective in a rural area since their ICERs in this area represent 
151% and 151%, respectively of their ICERs in an urban area.  
An initial question was whether or not comparing the CE of 
HIV/AIDS interventions across a rural area and an urban area 
would result in different CE results. This question is answered 
by these results. Indeed, the results presented in this chapter 
have shown that the CE of HIV/AIDS intervention depends on 
areas. However, bearing in mind the design of CE in this 
chapter, the results are expected to be similar. In fact, in each 
area, the CE of an intervention was analyzed on the same size 
cohort of patients, starting in the same HIV/AIDS state. The 
fact that the CE was shown to be different is at the centre of 
the rationale for this comparison. One would have expected 
the cost of interventions to be lower in an urban area. Better 
living standard in the urban area are expected to cushion the 
degradation of health status as result of HIV/AIDS,  reduce 
the need to seek care and consequently reduced the costs of 
intervention over time.  The higher costs in an urban area may 
in this case be explained by higher levels of usage of health 
care in an urban area.  
The comparison of HIV/AIDS interventions was grounded 
on the fact that the outcomes of HIV/AIDS interventions, 
particularly the CE, are a result of the interaction between 
area, individual patients and the intervention.  These factors, 
which have been theorized differently in the literature, are 
expected to prevail differently across a rural area and an urban 
area both in terms of trends and extent. In turn, these 
differences may influence the outcomes of interventions 
especially when one acknowledges that HIV/AIDS 
interventions do not necessarily target all contextual and 
individual factors. Due to the fact that the analysis took these 
interactions into account by pegging the progression of 
patients in HIV/AIDS states over time to projections of 
Spectrum Policy Modeling System, these results were 
expected, although there was no indication as to the trends and 
extent of CE across a rural area and an urban area or across 
HIV/AIDS interventions.  
The observed extent of CE across HIV/AIDS interventions 
can be explained using the components of cost-effectiveness. 
The fact that PMTCT was more cost-effective in the rural area 
means that, relative to USUAL CARE, it achieves relatively 
more effectiveness given additional costs in the rural area 
compared with the urban area.  Since PMTCT is conducted 
with pregnant women who use primary health care facilities in 
both rural and urban areas, it is likely that the risk of infection 
is detected and prevented.  By contrast, with low HIV 
screening rates, the impact of the epidemic is detected too late 
when health status has deteriorated. In the case of an urban 
area, better living conditions can cushion the impact, resulting 
in HAART interventions being relatively more effective in the 
urban area than in the rural area. 
Other studies have found that HIV/AIDS interventions have 
generally produced better effectiveness results in better socio-
economic contexts,[50] for example.  However, the rate of 
infections has been smaller in lower socio-economic areas in 
developing countries [51]. This supports the finding that, 
depending on the underlying factors, different outcomes of 
HIV/AIDS interventions can be observed. In a nutshell, one 
can conclude that the CE of HIV/AIDS interventions depends 
on the area. This conclusion has implications for South 
African policy makers.  Policy makers, who have been 
allocating resources based on other considerations, could 
include considerations of CE of HIV/AIDS interventions in 
socio-economic contexts to improve the efficiency of such 
HIV/AIDS interventions and so allocate their limited 
resources to the best effect.   
Finally, the results of this study need to be considered with 
care in light of the cost and effectiveness evidence used. The 
cost and effectiveness data have limitations and the results 
may suffer in terms of accuracy. Despite these drawbacks, the 
study addressed the issue of uncertainty in order to ensure that 
the findings of the study will be of value to policy makers in 
South Africa.  
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